On Monday, William Blair initiated coverage on LENZ Therapeutics Inc (NASDAQ: LENZ) stock, assigning an Outperform rating. The firm highlighted the company's potential as an emerging leader in eye care with its development of aceclidine, a treatment for presbyopia.
Presbyopia is the age-related loss of near visual acuity, affecting an estimated 128 million Americans. Current treatments primarily include eyeglasses, contacts, and various surgical procedures.
LENZ Therapeutics is advancing its aceclidine-based therapy, LNZ100, through clinical trials. Early April saw the release of top-line results from the Phase III CLARITY studies. These results have set the stage for a New Drug Application (NDA) submission anticipated in mid-2024, with a potential product launch targeted for mid-2025.
The Phase II and Phase III studies of LNZ100 have shown promising efficacy, with response rates of 71%-73% within 30 minutes of dosing and sustained effects throughout the day. Despite an increase in adverse events, such as an 11.5% headache rate, compared to the placebo group, the firm believes these are not significant enough to hinder the drug's success, drawing comparisons to other blockbuster eye care treatments.
Over the next year, multiple catalysts are expected for LENZ Therapeutics, including the planned NDA submission and the subsequent approval and launch of LNZ100. William Blair's analysis suggests that while LNZ100 will not be the first presbyopia treatment on the market, its efficacy could make it the best-in-class option, potentially attracting strategic partners due to its high market potential.
The firm projects that LNZ100 could achieve peak sales of $1 billion in the 2030s. This estimate may even be conservative, with the possibility of exceeding expectations through effective market execution by LENZ Therapeutics or the involvement of a strategic partner.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.